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To determine if women with Human Immunodeficiency Virus infection with severe 
degrees of immunosuppression are more predisposed to mortality from Gestational 
Trophoblastic Disease compared with HIV-infected women with less severe degrees of 
immunosuppression and Human Immunodefiency Virus (HIV) non-infected women. 
DESIGN: 
Retrospective review of case records. 
METHOD: 
A retrospective review was performed on all patients with Gestational Trophoblastic 
from 2003 to July 2007. A chart review was conducted and information captured on a 
data sheet. This retrospective audit was performed at the combined gynaecology 
oncology clinic of Inkosi Albert Luthuli Central Hospital. All information was kept 
confidential and was strictly for the purposes of the audit. 
STATISTICS: 
Factors associated with mortality were tested using Fisher's exact test. Odds ratios were 
reported as a measure of the strength of association. Breslow-Day's test for homogeneity 
in odds ratios was used to compare mortality in HIV-infected and HIV non-infected 
women. The analysis was done using Stata 9. 
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RESULTS: 
A total of 78 patients with Gestational Trophoblastic Disease were reviewed. There were 
53 patients with invasive molar pregnancy and 25 patients with choriocarcinoma. The 
HIV sero-prevalence was 31%. There were 15 deaths (19%). There were 8 HIV-infected 
(33%o) and 7 HIV non-infected (13%) women who demised. Of the 8 patients with CD4 
counts less than 200 cells/ uL, 7 patients demised. There were no mortalities amongst 
patients with CD4 counts more than 200 cells/uL. Of the 15 deaths, 5 HIV-infected 
patients and 5 HIV non-infected patients received chemotherapy. There were 5 patients 
admitted in very poor general condition precluding the administration of chemotherapy. 
Amongst the 10 patients who received chemotherapy and demised, the causes of death 
included widespread disease, multiorgan failure and toxicity due to chemotherapy. 
CONCLUSION: 
The overall survival of all patients managed with Gestational Trophoblastic Disease was 
82% in keeping with the expected high survival reported elsewhere. The majority of 
patients who demised were admitted in poor general condition and had abnormal blood 
profiles. Despite resuscitation, these patients failed to improve precluding the 
administration of chemotherapy which is the mainstay of treatment. Although the 
numbers are small, there is clear evidence that if patients are HIV-infected with CD4 
counts < 200 cells/uT, the mortality is high (75%). In contrast, the outcome is excellent if 




Gestational Trophoblastic Disease (GTD) encompasses a spectrum of abnormal 
proliferations of the trophoblast, ranging from benign to malignant forms of the disease. 
Conditions included under the term GTD include partial and complete hydatidiform 
mole, invasive mole, choriocarcinoma, placental site trophoblastic tumours and epitheloid 
trophoblastic tumours. Gestational Trophoblastic Tumour (GTT) refers to persistent GTD 
whilst Gestational Trophoblastic Neoplasia (GTN) refers to all GTD. Gestational 
Trophoblastic Disease is characterized by distinct clinical presentations, biochemistry and 
radiological features. In fact, GTD is one condition for which the diagnosis is based on 
clinical, biochemical and radiological investigations. Histology is usually not necessary 
and attempts to obtain histological confirmation may lead to torrential haemorrhage. 
Over the last few decades there have been differences in the management of GTD across 
the world. This situation had arisen mainly because the disease did not require 
histological confirmation and differences in staging systems and chemotherapeutic 
regimens utilized. Difficulties therefore arose in comparisons of treatment outcomes. 
With the advent of high resolution ultrasound and accurate tests for measuring serum In-
human chorionic gonadotrophin (P-HCG), there has been a trend to diagnose GTD 
earlier. The formation of the International Society for the Study of Gestational 
Trophoblastic Diseases (ISSGTD) led to consensus amongst world authorities in GTD. 
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This resulted in a uniform scoring system, agreement on the International Federation of 
Obstetrics and Gynaecology (FIGO) staging system and chemotherapeutic regimens 
(Kohorn, 2001). These guidelines have been shown to be feasible in clinical practice 
(Ngan, 2004). Early diagnosis, prompt referral to a tertiary centre and appropriate therapy 
produce the most optimal outcomes. 
Although the primary therapy for GTD is chemotherapy and monitoring, surgery has an 
important secondary role especially for complications of the disease and residual resistant 
disease. However, the decision to perform surgery should be judicious and executed with 
the advice of senior colleagues. Close monitoring during therapy is necessary as there is a 
tendency for complications to arise following institution of chemotherapy necessitating 
admission to a high-care or intensive care facility. Consideration of such an admission 
should be made prior to institution of chemotherapy. 
There is a tendency for GTD to occur more commonly in developing parts of the world 
which are plagued by epidemic proportions of human immunodeficiency virus infections. 
This has complicated the management of GTD especially because of co-morbid HIV-
related illnesses at the time of presentation as well as poor immunity reflected by low 
CD4 counts. Often, many developing parts of the world do not have access to anti-
retroviral therapy making treatment difficult. 
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CHAPTER 2 
THE EPIDEMIOLOGY OF GESTATIONAL TROPHOBLASTIC 
DISEASE 
Gestational trophoblastic disease is a rare entity making up only 1 % of all 
gynaecological malignancies. There is variation in the incidence of GTD due to many 
centres which have reported values based on hospital admissions rather than using the 
population as a denominator. Gestational trophoblastic disease occurs more commonly 
amongst the Asian belt. In Japan the incidence of hydatidiform mole is 1-2/1000 
pregnancies and is thought to be approximately three times higher than the incidence in 
Europe or North America (0.6 - 1.1/1000 pregnancies) (Takeichi, 1987; Schorage et al, 
2000). Incidence rates for choriocarcinoma are more limited due to the methods of 
diagnosis and definitions of disease. The incidence rate for choriocarcinoma in India is 
19/1000 pregnancies compared to 0.2 - 0.7/1000 pregnancies in North America and 
Europe. Recent publications have shown a decline of GTD in Korea, where the rate has 
fallen from 4.4/1000 pregnancies in the 1960s to 1.6/1000 pregnancies in the 1990s. 
Gestational Trophoblastic Disease affects predominantly young women and is one of the 
few gynaecological malignancies with high cure rates. In Africa and other parts of the 
world, the incidence of GTD is not reported. After one molar pregnancy, the risk of a 
repeated molar pregnancy is about 1% (Rice et al, 1989). Although this risk is low, 
patients are advised to have an ultrasound in the late first trimester to confirm the 
presence of a normal gestation (Berkowitz et al, 1998). 
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RISK FACTORS FOR GESTATIONAL TROPHOBLASTIC DISEASE 
Although several factors have been postulated to be associated with GTD, the aetiology 
remains unclear. A "J" shaped curve has been described with regards the age incidence in 
that young adults and women older than 40 years tend to have higher rates. Hydatidiform 
mole occurs in 0.6% of pregnancies if there is a past history of a molar gestation. 
Caucasian women tend to have lower incidences of GTD compared with Asian women. 
Women with blood group B tend to have higher incidences of molar pregnancies. Genetic 
factors may play a role as there is a higher risk of molar pregnancy if sisters have had 
molar gestations. 
Dietary factors are often linked to socioeconomic background. Previous reports from 
Taiwan implicated nutritional deficiencies such as albumin. Other reports noted that a 
high carotene intake is associated with a lower risk of molar pregnancies. The relative 
risk for smokers has been reported to be 2.6 if women smoke more than 15 cigarettes per 
day, compared with 2.2 for women who smoke less than 15 cigarettes per day. The 
relative risk of GTD in association with prior use of oral contraception was 1.9 (95% CI: 
1.2 - 3.0). It is thought that oral contraceptives slow the rate of HCG regression post 
treatment. Despite these findings it is not recommended that contraceptive prescribing 
patterns should change and the benefits of a repeat gestation, notably a molar gestation is 
still less with the use of the oral contraceptive. 
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CHAPTER 3 
THE PATHOLOGY OF GESTATIONAL TROPHOBLASTIC DISEASE 
HYDATIDIFORM MOLE 
Hydatidiform mole exists as a partial or complete mole. Complete moles are devoid of 
foetal tissue, membranes or umbilical cord structures. Macroscopically a common finding 
is the appearance of "grape-like" vesicles which correspond to grossly oedematous 
chorionic villi. Microscopically, there is abnormal trophoblastic proliferation and 
oedematous villi with absence of foetal vessels. Partial moles have few oedematous villi 
and the amount of molar tissue is usually less than that seen with complete moles. When 
a foetus is present, it has gross chromosomal and congenital abnormalities. 
Microscopically there are focal central cisterns and stromal fibrosis as well as abnormal 
trophoblastic proliferation. In situations when it is difficult to distinguish partial from 
complete moles, ploidy status may be useful since most partial moles are triploid. In 
addition to the aforementioned, trophoblastic tissue may invade the myometrium and/or 
adnexae. Such invasive patterns can be distinguished on imaging, including simple 
ultrasound, in combination with Doppler studies. The presence of villi distinguishes such 
molar proliferations from choriocarcinoma. 
Choriocarcinoma may be confined to the pelvis or may be metastatic in nature. 
Macroscopically, the tissue is grossly haemorrhagic, well circumscribed masses of tissue 
which may occur singly or in clusters. 
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The molar tissue generally penetrates into the myometrium and/or adnexae. Distant 
metastases are common to sites such as the brain, liver and lungs. About 50% of 
choriocarcinomas follow on molar gestations, 25% following abortions, 22.5% following 
a normal gestation and 2.5% following an ectopic gestation. Placental-site trophoblastic 
tumour is a rare entity with just over 100 cases described in the literature. These tumours 
arise from the intermediate trophoblast and secrete human placental lactogen (HPL) and 
small amounts of HCG (Kurman et al, 1984). Microscopically, these tumours contain 
mononuclear cells with large amounts of cytoplasm. The cells generally infiltrate 
between the muscle fibres of the uterus. Deep myometrial invasion is uncommon. 
However, widespread metastases and high mortality is well recognised. The current 




STAGING FOR GESTATIONAL TROPHOBLASTIC DISEASE 
The diagnosis of gestational trophoblastic tumour is based on clinical, radiological and 
biochemical findings. In order to determine prognosis and apply appropriate treatment 
regimens, many systems based on clinical, anatomical and prognostic systems have been 
utilised worldwide. The formation of the ISSGTD led to the incorporation of the FIGO 
and World Health Organisation (WHO) classifications. This resulted in a new 
staging/classification system to be utilised worldwide. This system has been approved by 
the council of FIGO (FIGO Oncology Committee Report, 2002). Previous classification 
systems such as the National University Singapore system (Tham & Ratnam, 1998) have 
been incorporated into the current FIGO staging/scoring system. Blood group has been 
omitted from the FIGO scoring system as its prognostic value is of doubtful significance. 
Independent predictors of mortality include: antecedent term pregnancy, liver or brain 
metastases and long interval between previous pregnancy state and current presentation 
(Bower et al, 1997). 
Changes in the current accepted staging system as described by Kohorn (2001), reflect a 
change in the risk score for liver metastases from a score of 2 to 4. Metastatic lung 
disease may be detected by chest X-ray rather than computerised axial tomography 
scanning (CAT). If lung lesions are present, then the best imaging for brain and 
abdominal disease is magnetic resonance imaging (MRI). 
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However, CAT scanning is commonly utilised for this purpose. This staging system has 
been shown to produce a better outcome than the modified WHO prognostic index score 
and is practical in the clinical setting (Ngan, 2004). The current nomenclature for staging 
is to state the FIGO stage followed by the risk score e.g., FIGO III: 7. The FIGO stages 
and WHO risk-scoring are reflected in Tables II and III respectively. A score of <6 
represents low-risk disease and > 7 reflects high-risk disease. Low-risk disease is treated 
with single agent methotrexate, whilst high-risk disease is best treated with multi-agent 
chemotherapy (Etoposide, Methotrexate, Actinomycin, Cyclophosphamide and Oncovin). 
A retrospective analysis by Hancock et al (2000), reviewed the outcomes of patients 
managed according to this revised classification system. It was found that the risk scoring 
system correlated far better with outcome than the modified WHO prognostic index 
score. Thus, the new classification/scoring system will result in uniform management 
throughout the world and form the basis for the comparison of treatment results. 
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CHAPTER 5 
THE DIAGNOSIS OF GESTATIONAL TROPHOBLASTIC DISEASE 
The diagnosis of molar pregnancy is based on the findings of a triad of: clinical, 
biochemical and radiological studies. The clinical presentation includes a period of 
amenorrhoea, vaginal bleeding, sometimes with the passage of vesicles or bunch of 
"grape-like" structures per vagina, uterine enlargement larger than the period of 
amenorrhoea, hyperthyroidism, hyperemesis gravidarum and pre-eclampsia. With the 
advent of high resolution ultrasound, molar pregnancy can be detected in the first 
trimester. For complete moles, the mean gestational age at diagnosis with ultrasound is 
12.4 weeks compared with 14.3 weeks at which partial moles are diagnosed (Lindholm 
and Flam, 1999). 
The classic ultrasound feature of a molar gestation is the description of an enlarged uterus 
containing an echogenic mass with cystic spaces (Benson et al, 2000). Further ultrasound 
evaluation including Doppler is able to detect the presence of invasive molar pregnancy. 
About 15% to 25% of patients with complete molar gestations have theca lutein cysts and 
ovarian enlargement of more than 6cm detected with the use of ultrasound (Montz et al, 
1988). Due to trophoblastic proliferation elevated serum quantitative P-HCG levels in 
conjunction with the clinical and radiological findings are the cornerstone for the 
diagnosis of GTD. Serum P HCG levels correlate with the volume of trophoblastic 
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tumour and findings of > 92 000 U/L in association with an absent foetal heart are 
indicative of complete molar gestations (Romero et al, 1985). 
Choriocarcinoma may develop after any type of gestation, but commonly follows a 
previous molar gestation in about 50% of patients. Postpartum choriocarcinoma is well 
described and often the diagnosis is missed, resulting in late presentation with fatal 
consequences (Nugent et al, 2006). Clinical features include vaginal bleeding, anaemia, 
hyperthyroidism and in some cases, features of metastatic disease such as haemoptysis. 
The commonest metastatic sites include the lungs (80%), liver (10%), brain (10%) and 
vagina (30%), although a rare site in the hand has been described (Afshar et al, 2007). 
Lung involvement may be asymptomatic or patients may present with mild respiratory 
discomfort. Occasionally, the chest X-ray may be negative and CT scanning may reveal 
multiple lung lesions (Moodley et al, 2004). Torrential vaginal bleeding due to vaginal 
lesions may result in haemorrhagic shock. Prompt resuscitation, vaginal packing, pelvic 
angiography and arterial embolisation are highly effective in salvaging such patients 
(Moodley et al, 2003a). 
Persistent molar pregnancy includes molar tissue evident after suction curettage, invasive 
moles and choriocarcinomas. The majority of post-molar GTD are invasive moles or 
persistent moles (70% to 90%) (Lurain et al, 1983). It was previously thought that partial 
moles do not transform into choriocarcinomas. However, both partial and complete moles 
are at risk of progressing to malignant disease (Seckl et al, 2000). The risk is 5% for 
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partial moles and 20% for complete moles. The diagnosis of post molar GTD as accepted 
by FIGO include: 
1. The presence of histological choriocarcinoma 
2. Persistent HCG values 6 months post evacuation of the uterus 
3. Rise of HCG of 10% or greater for 3 values or more over at least 2 weeks on days 
1,7 and 14. 
4. Four HCG values or more demonstrating a plateau (± 10%) over a 3 week period; 
days 1,7, 14 and 21. 
Placental site trophoblastic tumour is a rare form of GTD (1-2% of all GTD) (Ajithkumar 
et al, 2003), often diagnosed incidentally by histopathology of a uterine or endometrial 
curetting specimen. A high index of suspicion needs to be maintained especially if the 
HCG values are unusually low. The characteristic features of placental site trophoblastic 
tumours are low levels of serum HCG, secretion of human placental lactogen (HPL), 
resistance to chemotherapy and unpredictable behaviour with the risk of metastatic 
spread. Fisher et al (1992), demonstrated that placental site trophoblastic tumour may 
arise following a normal term gestation or hydatidiform mole or previous molar 
gestations (12%) (Moore-Maxwell & Robboy, 2004; Moodley, 2007). Although most 
patients are in the reproductive age group, placental site trophoblastic tumour can present 
in menopausal women (Colleen et al, 1998). 
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The common clinical manifestation is vaginal bleeding following a period of 
amenorrhoea. Of interest is that most such gestations occur after a female gestation and 
can be associated with nephritic syndrome (Lathrop et al, 1988; Hui et al, 2000 & 
Feltmate et al, 2001). Although in most instances the disease is confined to the uterus, 
distant metastases have been documented. Papadopoulos et al (2002), reported that 
distant metastases were found in 30% of their patients managed at the Charing Cross 
Hospital in the United Kingdom. Radiological findings include a heterogenous, 
hyperechoic mass with multiple cystic spaces within the myometrium (Allen et al, 2006). 
These features may resemble the radiological features of other types of GTD. The clinical 
outcome of patients with placental site trophoblastic disease depends on many factors 
including, interval since last pregnancy and whether the disease is localised or metastatic. 
Mortality is highest if there are brain metastases (Lathrop et al, 1988). Surgery in the 




THE GENETICS AND COMPLICATIONS ASSOCIATED WITH 
GESTATIONAL TROPHOBLASTIC DISEASE 
Most complete molar gestations have 46 XX karyotype. It is thought that both 
chromosome pairs are derived from paternal chromosomes. Fertilisation of an empty 
ovum by a haploid set of chromosomes followed by duplication of the chromosomes is 
thought to be the genetic basis (Androgenesis) (Wake et al, 1978). Dispermy accounts for 
46 XY moles which occur in about 4% of cases (Ohama et al, 1981). Dispermic triploidy 
forms the genetic basis of partial moles and result from the fertilisation of an ovum by 
two spermatozoa. The occasional tetraploid karyotype in partial moles has also been 
described (Vejerslev et al, 1987). The possible karyotypic patterns seen with partial 
moles include: 69 XXY (70%), 69 XXX (27%) and 69 XYY (3%) (Lawler et al, 1982). 
The risk of a complete mole progressing to invasive malignancy is in the order of 20%. 
However, based on genetic analysis of choriocarcinomas, it has been difficult to trace 
back an origin to complete moles (Chaganti et al, 1990). Arima et al (1995), using 
polymerase chain reaction analysis of nine post-molar tumours, demonstrated that 
choriocarcinomas developed from a full term gestation preceding a complete molar 
pregnancy. Placental site trophoblastic tumours genetically, may arise from molar 
gestations or from previous normal term gestations. 
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The cytogenetics of placental site trophoblastic tumours is essentially diploid in origin 
(Lathrop et al, 1988). Ichikawa et al (1998), demonstrated p53 expression in placental 
site trophoblastic tumour cells. Chromosomal gains and losses have been described with 
choriocarcinoma including deletion at 8p and amplification at 7q (Ahmed et al, 2000). 
There are many complications related to molar gestations such as pre-eclampsia, 
hyperthyroidism, hyperemesis gravidarum, torsion or rupture of theca lutein cysts, acute 
respiratory distress, uterine sepsis, perforation and haemorrhage into viscera. 
Hyperthyroidism is often biochemical and is clinically diagnosed in about 10% of molar 
gestations. Clinical hyperthyroidism is managed with the use of anti-thyroid drugs and 
beta-blockers. Hyperthyroidism should be corrected prior to surgery to prevent thyroid 
crises. Uterine perforations usually occur during suction evacuation of a soft, enlarged 
uterus. Bleeding from trophoblastic tissue can be spontaneous or following chemotherapy 




MANAGEMENT OF NON-INVASIVE MOLAR PREGNANCY 
Non-invasive molar pregnancy is characterised by the absence of molar tissue penetrating 
the myometrium and or adnexae as detected by ultrasound and colour flow Doppler. Such 
patients require basic investigations, resuscitation, preparation of the cervix with Lamicel 
hygroscopic dilator and suction curettage in theatre (Moodley, 2007). Basic 
investigations include: 
1. Blood tests 
a. Full blood count, coagulation profile (INR/PTT), renal function (Urea and 
Electrolytes), Rhesus blood group 
b. Thyroid function test 
c. Quantitative p-HCG 
d. HIVELISA antibody test & CD4 count 
2. Radiological tests 
a. Ultrasound examination of the pelvis and abdomen 
b. Chest X-ray 
c. Doppler flow of the uterus to exclude invasion 
d. CT/MRI of the brain and abdomen only if the chest X-ray demonstrates 
lung metastases 
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The cervix should be softened with Lamicel hygroscopic dilator and agents which 
stimulate uterine contractions such as prostaglandins, should be avoided to prevent 
embolisation of trophoblastic tissue to the lungs and malignant complications (Schlaerth 
et al, 1988; Tidy et al, 2000). Suction curettage is performed under oxytocic infusion to 
prevent uterine perforation. Careful observation of the patient post evacuation is 
necessary, sometimes in a high-care facility especially if biochemical abnormalities such 
as hyperthyroidism are present prior to suction curettage. Contraception should be 
prescribed and weekly serial P-HCG levels measured. These levels should become 
negative within a 6 month period, failing which, chemotherapy is advocated. 
THE ROLE OF PROPHYLACTIC CHEMOTHERAPY 
Most patients who require suction evacuation of uterus will have full resolution of the 
disease as judged by negative p-HCG values within 6 months post evacuation. A 
minority of patients will require chemotherapy based on the diagnosis of persistent molar 
gestations. As a result the issue of prophylactic chemotherapy is controversial. In this 
situation single agent methotrexate has been administered for several hours during 
evacuation of molar contents or hysterectomy (Sivanesaratnam & Ng, 1977). The 
disadvantages include toxicity in the background of a large number of patients who will 
not require chemotherapy and trophoblastic neoplasia, which takes many years to 
manifest, is then usually resistant to chemotherapy (Curry et al, 1975). 
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Kim et al (1986), demonstrated that in high-risk patients prophylactic chemotherapy is 
associated with a reduction of post-molar GTD from 47% to 14%. It therefore appears 
that the risks of chemotherapy outweigh the benefits and should no longer be current 
practice. 
MANAGEMENT OF GESTATIONAL TROPHOBLASTIC NEOPLASIA 
Invasive molar pregnancy, choriocarcinoma and persistent molar pregnancy are regarded 
as gestational trophoblastic neoplasia. These patients should be referred to a tertiary level 
centre for expert care. The criteria for diagnosis have been described. These patients 
should be staged according to the FIGO 2000 staging and risk scoring performed 
according to the recommendations of the International Society for the Study of 
Gestational Trophoblastic Diseases (ISSGTD) (Appendix) (Soper et al, 2004). Low-risk 
patients with a score of < 6 are managed with single agent chemotherapy e.g., 
methotrexate, on a weekly basis. High- risk patients with a score of > 7 are managed with 
multi-agent chemotherapy in the form of EMA CO (Etoposide, Methotrexate, 
Actinomycin D, Cyclophosphamide and Oncovin). The EMA CO regimen is well 
tolerated and Newlands et al (1998), documented the cumulative 5 year survival of 
86.2% (95%CI: 81.9 - 90.5%). Kim et al (2007), also documented beneficial outcomes 
with early treatment of patients with high-risk molar pregnancy. Recently El-Lamie et al 
(2006), described the omission of the CO part of this regime to reduce toxicity, using 
EMA EP (Etoposide, Cisplatinum) for resistant cases and incorporation of paclitaxel in 
the third-line management. With these protocols, 81.4% of patients with high-risk 
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metastatic gestational trophoblastic tumours could be cured. Chemotherapy response is 
monitored by serial [3-HCG estimations after each cycle of chemotherapy. Empirically, 
two and three more cycles are given to low and high-risk patients, respectively, once the 
HCG levels have become negative. Haemorrhage from an invasive molar pregnancy may 
occur if evacuation of the uterus is attempted and therefore primary chemotherapy is 
recommended (Soper et al, 2004). 
Placental site trophoblastic disease is not staged according to the FIGO system and the 
primary therapy is hysterectomy. These tumours are inherently resistant to chemotherapy. 
Metastatic placental site trophoblastic disease is treated with hysterectomy followed by 
adjuvant chemotherapy. Chemotherapy regimens in this situation include EMA CO or 
EMA EP combinations (Randall et al, 2000; Behtash et al, 2008). 
ROLE OF SURGERY IN GESTATIONAL TROPHOBLASTIC DISEASE 
Whilst chemotherapy is the primary form of treatment, surgery has an important 
secondary role especially for complications. However, surgery in this setting carries with 
it risks and should only be performed by experienced personnel. It is judicious to have 
intensive care unit facilities as backup to support the surgical interventions. A wide range 
of surgical interventions have been described including laparotomy for uterine sepsis or 
perforation, torsion of theca lutein cysts, thoracotomy and craniotomy for resection of 
isolated residual resistant nodules, surgery to control internal haemorrhage and 
conservative techniques such as angiography and embolisation of feeding vessels such as 
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the internal iliac arteries. Lurain et al (2006), reported that surgery was necessary in 48% 
of 50 patients with high-risk GTD, of which 87.5% were cured. Soper et al (2007), 
recently described a multimodahty approach to central nervous system metastases using 
chemotherapy, craniotomy and stereotactic surgery with successful outcomes. 
Hysterectomy is indicated for uterine complications and is an acceptable procedure for 
the primary treatment of an older patient with molar pregnancy who does not desire 
future fertility (Soper et al, 2004). Otherwise resection of an isolated residual resistant 
nodule within the uterus is feasible for the younger patient who desires future fertility. 
Ligation of feeding arteries such as the uterine or internal iliac artery is feasible but 
should only be performed if angiographic embolisation has failed. This is due to the high 
success rate of embolisation techniques (Tse et al, 2007). 
While gestational trophoblastic disease can be cured, 10-25% of patients with metastatic 
disease die of this disease. Mortality from this disease, although rare, can be linked to 
certain parameters that confer a poor prognosis. The prognostic factors as set out by the 
International Federation of Obstetrics and Gynaecology (FIGO) (FIGO Oncology 
Committee, 2002) include age, antecedent pregnancy (mole/abortion/term), interval 
between antecedent pregnancy and start of chemotherapy, pre-treatment P-Human 
Chorionic Gonadotrophin (HCG) levels, largest tumour size, site of metastases, number 
of metastases and previous failed chemotherapy. A modified World Health Organization 
(WHO) scoring system has been combined with the FIGO staging. In 2000, FIGO 
accepted this WHO scoring system based on these prognostic factors. 
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Gestational trophoblastic disease has an excellent response rate to chemotherapy with 
cure rates of almost 100% for low-risk disease and 70% for high-risk GTD treated with 
chemotherapy. Although the mortality from high-risk metastatic GTD was about 90% 
with chemotherapy, this has been converted to a cure rate of 92% or greater (Kohorn et 
al, 2000). 
OUTCOMES OF PATIENTS WITH GESTATIONAL TROPHOBLASTIC 
DISEASE 
The response to chemotherapy is excellent. The risk of a patient presenting with a second 
mole after a partial or complete molar pregnancy is in the order of 1-2% (Berkowitz et al, 
1998). Patients are advised not to conceive for 12 months post treatment. There is no 
evidence that the oral contraceptive pill increases the risk of malignant sequelae or 
regression of the HCG levels (Morrow et al, 1985). Non-metastatic disease has a cure 
rate of almost 100% (Roberts & Lurain, 1996). Up to 13% of patients with high-risk 
disease will develop recurrence (Mutch et al, 1990). Most patients have normal 
subsequent pregnancies. Generally there are no reports of increased chromosomal or 
congenital abnormalities in subsequent pregnancies. However, Matsiu et al (2003), 
reported that there was a 40% greater chance of abnormal pregnancy outcomes 
(abortions, stillbirths, repeat molar gestation) in patients who conceived within 6 months 
of completing chemotherapy compared with patients who waited for more than 12 
months after completing chemotherapy (10%). An ultrasound scan in the first trimester 
following previous GTD is recommended. 
20 
CHAPTER 8 
THE IMPACT OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
INFECTION ON GTD 
The literature describing the association and impact of the HIV infection amongst women 
with GTD is limited to case reports. Ojwang et al (1992), recommended that the Human 
Immunodeficiency Virus (HIV) infection be included in the list of WHO prognostic 
factors for choriocarcinoma. In the three cases described by Ojwang et al (1992), (all 
HIV infected, CD4 counts not documented) one had a prolonged course of chemotherapy 
without remission, a second responded only after hysterectomy was combined with 
chemotherapy and the third had extensive metastases with tumour in unusual sites (nasal 
metastases) despite low risk factors. Since the clinical manifestations of all three were 
severe, HIV infection was proposed as a poor prognostic factor for choriocarcinoma. 
Moodley et al (2003b), described the successful use of cytotoxic chemotherapy for 
gestational trophoblastic disease in an HIV infected patient and also demonstrated 
successful outcomes in HIV-infected patients with reasonable levels of immunity. Failure 
to treat such women would have resulted in their demise much earlier than from the HIV 
infection itself. Ashley, in a case presentation and literature review in 2002, postulated 
that it is possible that in AIDS (Acquired Immune Deficiency Syndrome) patients, failure 
of an immune response to destroy tumour cells (trophoblastic emboli which are shed into 
maternal serum are usually destroyed by maternal immune response) leads to metastatic 
lesions, thus predisposing such patients to the development of choriocarcinoma. 
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The role of HIV infection in patients with Gestational Trophoblastic Disease is of 
importance to much of Africa and needs to be defined as in a large part of Sub-Saharan 
Africa, HIV infection is epidemic and there exists an increased chance of finding patients 
with concurrent gynaecological malignancies and HIV infection. Chemotherapy is one of 
the widely used treatment modalities in cancer with its known toxic side-effects that may 
further compromise immunity which may lead to increased morbidity and mortality 
unrelated to the malignancy itself. The use of these cytotoxic agents in patients with HIV 
infection poses many management and ethical problems. The benefits and risks 
associated with administering chemotherapy, leading to further immunosuppression in 
HIV-infected patients, needs to be carefully analysed and may require dosage 
adjustments, co-administration of granulocyte colony stimulating factors (GCSF) to 
support bone marrow function and/or the concurrent use of anti-retroviral therapy. The 
successful use of cytotoxic chemotherapy in combination with anti-retroviral therapy has 
been described by Moodley et al (2003b). 
There are case reports and retrospective studies (Moodley et al, 2003b; Ashley, 2002; 
Moodley et al, 2001; Tangtrakul, 1998; Moodley et al, 2003c) describing concurrent HIV 
infection and gestational trophoblastic disease in patients, but no randomized controlled 
studies or guidelines exist outlining management. In addition there is no literature 
documenting the causes of mortality amongst women with gestational trophoblastic 
disease in relation to HIV serostatus. We performed a retrospective analysis of causes of 
mortality in patients with gestational trophoblastic disease and HIV infection with 
varying degrees of immuno-suppression and compared their profiles with the causes of 
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mortality in HIV non-infected patients with Gestational Trophoblastic Disease. After 
institutional ethical approval was granted, the audit was performed for all patients with 
trophoblastic disease managed at Inkosi Albert Luthuli Central Hospital, which is a large 
tertiary hospital serving the indigent population of KwaZulu Natal, South Africa. The 
study period included patients treated from 2003 to 2007. 
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CHAPTER 9 
STUDY: PROFILE OF MORTALITY AMONGST WOMEN WITH 
GESTATIONAL TROPHOBLASTIC DISEASE INFECTED WITH THE HUMAN 
IMMUNODEFICIENCY VIRUS (HIV) IN RELATION TO HIV 
NON-INFECTED WOMEN 
AIM: 
1. To establish causes of mortality in women with GTD in association with HIV 
infection in relation to HIV non-infected women. 
2. To determine if changes in management are necessary 
PATIENTS AND METHODS 
After institutional ethical approval was obtained, all patients with Gestational 
Trophoblastic Disease managed in the combined gynaecology oncology clinic at Inkosi 
Albert Luthuli Central Hospital were recruited for the study. This hospital is a large 
tertiary referral hospital for the province of Kwa-Zulu Natal serving mainly the indigent 
population. The study period included a review of records of patients treated from 2003 




Factors associated with mortality were tested using Fisher's exact test. Odds ratios were 
reported as a measure of the strength of association. Breslow-Day's test for homogeneity 
in Odds Ratios was used to compare mortality in HIV infected and HIV non-infected 




There were a total of 78 patients with trophoblastic disease managed over the study 
period. The mean age of all patients was 31 years (16 - 50 years). Of all patients, 68 were 
under 40 years of age. There were 53 patients with a diagnosis of invasive molar 
pregnancy and 25 patients with choriocarcinoma. Table IV (Appendix) illustrates the 
general parameters for the 78 patients including the International Federation of Obstetrics 
and Gynaecology (FIGO) staging, site of metastases, chemotherapy, side effects of 
chemotherapy and Intensive Care Unit (ICU) monitoring. In terms of race, there were 69 
African patients, 2 Coloured and 7 Indian patients with GTD. There were 24 patients 
who were HIV-infected. The HIV seroprevalence amongst patients with GTD was 
therefore 31%. There was one HIV-infected patient admitted in a critically ill condition 
and whose CD4 count was not determined. Of the 23 HIV-infected patients with known 
CD4 counts, 8 patients had CD4 counts less than 200 cells/uT (36%). In total there were 
15 deaths (19%). All 15 mortalities occurred amongst African patients. There were 11 
deaths amongst patients younger than 40 years of age (16%). There were 8 (33%) HIV-
infected patients and 7 HIV non-infected (13%) who demised, (OR: 2.7 CI: 0.8-9.0, p= 
0.1). Majority of patients who demised were managed as choriocarcinoma (87%). 
Mortality was significantly related to CD4 counts. Of the 8 patients with CD4 counts less 
than 200 cells/uL, 7 patients demised. 
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There were no mortalities amongst HIV-infected patients whose CD4 counts was more 
than 200 cells/uL, compared with 7 deaths amongst 8 patients (88%) whose CD4 counts 
was less than 200 cells/uL (p = 0.001). 
Twelve patients (50%) managed as FIGO stage 1II/IV demised compared to 3 (6%) 
patients with Stage I/II disease (p < 0.001). Of the 15 patients who demised there were 3 
patients with brain metastases, 8 patients with lung metastases, 2 with liver metastases, 1 
with gastrointestinal metastases and 1 with metastases to the scalp. Of the 13 patients 
who required arterial embolisation for uncontrollable haemorrhage, 9 were successful. Of 
the remaining 4 patients in which embolisation was unsuccessful, one required bronchial 
artery embolisation and died due to pulmonary haemorrhage, one died from 
hypovolaemic shock despite arterial embolisation for intrabdominal bleeding. Of the 
remaining two patients, one required a total abdominal hysterectomy and the other 
internal iliac artery ligation for persistent bleeding following embolisation. Both these 
patients survived. There were 5 patients admitted in very poor general condition 
precluding administration of chemotherapy. The reasons for their poor general conditions 
are reflected Table V. Majority of these patients were HIV-infected. The numbers of 
patients with abnormal blood profiles on admission were: anaemia (n=33) and 
hyperthyroidism (n=27). Mortality was significantly higher in patients with abnormal 
blood profiles (n=12; 27%), compared with patients who had normal blood profiles (n=2; 
6%), (p = 0.03). Of the 15 patients who demised and who had abnormal blood profiles, 1 
patient had renal failure; 8 patients had hyperthyroidism; 10 patients had anaemia and 6 
patients had both anaemia and hyperthyroidism. 
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In total, 73 out of 78 patients received chemotherapy (94%). Of the patients who received 
chemotherapy and demised, 6 received single agent chemotherapy in the form of 
methotrexate whilst 4 patients received multi-agent chemotherapy (etoposide, 
methotrexate, actinomycin, cyclophosphamide, and Oncovin). Of the 15 patients who 
demised, 5 patients did not receive chemotherapy and demised of their disease. All 63 
patients who survived received some form of chemotherapy (p < 0.001). Amongst the 10 
patients who received chemotherapy and demised, the causes of death were: widespread 
disease (n=5); multiorgan failure, septicaemia and neutropaenia (n=2); widespread 
disease, multi-organ failure, septicaemia and neutropaenia (n=2); and cause unrelated to 
the primary disease or chemotherapy (rheumatic cardiac disease) (n=l). One patient 
demised due to a combination of hypertension, hyperthyroidism, and cardiac failure in 
the background of Rheumatic heart disease. 
Of the 15 deaths, 5 HIV-infected patients and 5 HIV non-infected patients received 
chemotherapy. Of the 6 patients requiring intensive care-unit management for severe 
respiratory distress, 5 demised (83%), due to the extent of their disease. Two of these 
patients were HIV-infected. Only 13% of patients not requiring intensive care died (p = 
0.001). In total, there were 4 patients whose demise was related to side effects of 
chemotherapy. Of these 4 women, one commenced chemotherapy with a CD4 count of 
62 cells/uL in conjunction with anti-retroviral therapy and subsequently developed 
neutropaenia, septicaemia, and multiorgan failure. Of the remaining 3 HIV non-infected 
patients, the cause of mortality was related to neutropaenia, septicaemia, multiorgan 
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failure and atrial fibrillation. Of all patients who developed myelotoxicity, the majority 
(over 90%) developed grade 2-3 myelotoxicity. 
Of the 24 HIV-infected patients, 21 (88%) patients received chemotherapy. Of these, 16 
were successfully treated (76%) whereas 5 demised. The outcomes of the 8 patients with 
CD4 counts <200 cells/uL are illustrated in Table VI. The profile of mortality amongst 
HIV non- infected patients is reflected in Table VII. 
The majority (75%) of HIV- infected patients with CD4 counts <200 cells /uL presented 
with advanced FIGO stages (III/ IV), compared to 80% of HIV-infected patients with 
CD4 count >200 cells /uL who presented with early FIGO stages (1/ II) (p=0.02). Further, 
only 26% of HIV non-infected patients presented with advanced FIGO stages (III/IV) 





Gestational trophoblastic disease encompasses a spectrum of proliferative disorders of the 
trophoblast with hydatidiform mole, choriocarcinoma and placental site trophoblastic 
tumour (PSTT) being the important clinical entities. The incidence of molar pregnancy 
varies geographically with the highest rates in Eastern countries. The incidence rate of 
molar pregnancy in South-East Asia ranges from 1-2/1000 pregnancies in Japan and 
China (Takeichi, 1987; Schorage et al, 2000) to 12/1000 in Indonesia (Farid et al, 1984). 
Many factors are associated with the incidence of molar pregnancy, such as maternal age, 
diet, gravidity, past pregnancy history, genetics and ethnicity (Teoh et al, 1972). The 
incidence rate of choriocarcinoma also varies geographically and may be under-reported 
since histological confirmation is not obtained in some centres in the world. 
Gestational trophoblastic disease is associated with an excellent prognosis due to the 
inherent sensitivity of tumour tissue to chemotherapy. Since GTD is a relatively 
uncommon condition, a high index of suspicion is always necessary by the practising 
clinician. Any women in the reproductive age group with the presentation of metastatic 
disease should be suspected of having trophoblastic disease. The diagnosis of GTD is 
usually based on clinical, biochemical and imaging parameters. As such, 
choriocarcinoma does not require a tissue diagnosis with its attendant morbidity. 
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Whilst non-invasive hydatidiform mole is treated with suction curettage as the definitive 
procedure, invasive molar pregnancy and choriocarcinoma are best treated primarily with 
chemotherapy. The recommended management of PSTT is surgery in the form of 
hysterectomy, with chemotherapy being reserved for advanced stage disease. 
The implementation of the FIGO oncology committee recommendations have 
standardised the treatment of GTD worldwide and now allows appropriate comparisons 
of results internationally (FIGO Oncology Committee, 2002). Based on this scoring 
system, patients with a score of < 6 should receive single agent methotrexate or 
actinomycin D, whilst patients with a score of > 7 should be treated with multi-agent 
chemotherapy. Newlands et al (1991), demonstrated excellent responses of over 80% 
with the EMA CO regime, which has now become the first-line chemotherapy for high-
risk disease. It appears from the literature that there are mixed results of outcomes of 
patients with GTD and co-existing HIV infection. However, it would also appear that the 
management of HIV-infected patients with reasonable levels of CD4 counts and GTD is 
successful with chemotherapy and in the short term patients would otherwise demise 
from GTD rather than HIV infection itself (Moodley et al, 2003c). The management of 
GTD should preferably be centralised to accumulate expertise and provide a specialised 
service to such patients. This is especially true now with the HIV epidemic and the co-
existence of GTD in patients with HIV infection. 
Although the outcomes of patients with GTD are largely positive, mortalities have been 
described. A retrospective review of 2033 gynaecological admissions at a referral centre 
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in Nigeria, showed that choriocarcinoma is one of the leading causes of mortality of the 
79 deaths documented (Anya et al, 2006). El-Lamie et al (2006), in a retrospective report 
of 261 patients treated for GTD, over an 11 year period documented a 20% mortality rate. 
The causes of mortality included acute respiratory distress syndrome prior to treatment as 
well as treatment complications. Further, the presence of brain and/or liver metastases 
correlated with poor survival, followed by chemotherapy resistance and the type of 
antecedent pregnancy. 
Papadapoulos et al (2002), reported a mortality rate of 21% amongst 34 patients with 
PSTT. All deaths (n=7) were disease-related with lung involvement and antecedent 
pregnancy of 4 years and more being high-risk factors for mortality. The WHO scoring 
system for GTD is not utilised in the management of PSTT and has not been shown to 
correlate with outcome (Papadapoulos et al, 2002). Song et al (1998), reported a 
reduction in mortality from >90% to <20% when chemotherapy was introduced in the 
management of choriocarcinoma. Ebeling et al (1995), reported a mortality rate of 8.6% 
due to the disease and noted that outcomes where significantly better for patients who 
were treated mainly at specialised centres. Postpartum choriocarcinoma usually has a 
worse prognosis due to delay in diagnosis. Nugent et al (2006), documented a mortality 
rate of 6% (2/35) and a mean survival of 7.8 years (l/21years) amongst patients with 
postpartum choriocarcinoma. 
Choriocarcinoma after a non-molar pregnancy, usually presents five to six months post 
delivery. Tidy et al (1995), documented a mortality of 21% after a live birth compared to 
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6% after a molar abortion. Maternal mortality in patients with hydatidiform mole is 
mainly due to the primary disease-related complications such as severe haemorrhage and 
coagulopathy (Tsakok et al, 1983). 
Cisse et al (2002), have recommended prophylactic hysterectomy after molar pregnancy 
to prevent the occurrence of choriocarcinoma. They reported a mortality rate of 49.2% 
and an average survival of 48 months amongst 61 patients with choriocarcinoma treated 
in Senegal. Our results demonstrate that the majority of deaths occurred in patients with 
advanced (F1GO) stage disease. The high mortality amongst patients with brain and lung 
metastases (Table IV) is in keeping with the findings of El-Lamie et al (2006). Of note is 
that of the 8 patients with lung metastases and HIV-infection, 7 patients demised. These 
patients were noted to be in poor general condition, developed respiratory distress and 
succumbed despite attempts to resuscitate and provide Intensive Care Unit (ICU) 
ventilation for some of them. 
The occurrence of mortalities amongst only African patients reflects the demography of 
the province of KwaZulu Natal, South Africa. The background HIV-seroprevalence in 
the province of KwaZulu Natal for years 2003, 2004 and 2005 were 37.5%, 40.7% and 
39.1%, respectively, as reported from the antenatal clinic attendees. Over the period from 
2003 to 2007, there were 24 HIV-infected patients with GTD resulting in a HIV 
seroprevalence of 31%. This high figure is also reflective of the high background 
prevalence of HIV in the province of KwaZulu Natal as compared to the rest of South 
Africa. 
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A significantly larger percentage (29% vs. 13%) of mortalities occurred amongst HIV-
infected women. A statistically significant increase in mortality was noted amongst HIV-
infected patients with CD4 counts less than 200 cells/uL compared with HIV-infected 
patients with CD4 counts greater than 200 cells/uL (p < 0.001). An evaluation of these 
mortalities demonstrates that these patients had widespread metastases, co-morbid 
conditions such as pneumonia, renal failure, jaundice and biochemical abnormalities. In 
contrast, one of the 7 HIV-infected patients who demised was admitted in good general 
condition, but developed side effects and multiorgan failure secondary to chemotherapy. 
Review of the 17 HIV-infected patients who were treated and survived, demonstrate that 
they were admitted in good general condition with no co-morbidities and 15/16 patients 
had CD4 counts greater than 200 cells/uL. Two patients with CD4 counts less than 200 
cells /uL were commenced on chemotherapy in spite of respiratory involvement to treat 
and improve lung function. It is appreciated that the administration of chemotherapy to 
women with CD4 counts < 200 cells/ul is problematic. However, in the absence of 
literature, experience demonstrates that it is not feasible to administer chemotherapy in 
these scenarios 
Only one HIV non-infected patient admitted with co-morbidity i.e., pneumonia, demised 
without receiving chemotherapy. The other mortalities amongst the HIV non-infected 
patients were mainly due to treatment-related side-effects. Likewise, all HIV non-infected 
survivors had no co-morbidities on admission. In view of the rarity of GTD in association 
with HIV infection, literature is based mainly on case series. The findings from this study 
corroborates our previous analysis (Moodley et al, 2003b) of outcomes of treatment in 
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relation to HIV serostatus providing evidence of good outcomes if HIV-infected patients 
have CD4 counts greater than 200 cells /uL. However, our current study provides 
evidence of mortality and reasons thereof, if the CD4 counts are less than 200 cells /\iL, 
especially if co-morbid conditions are present on admission. Although HIV clinics are 
available in our environment and provide anti-retroviral therapy, the process of acquiring 
anti-retroviral therapy is a lengthy one. 
Ojwang et al (1992), described unusual presentations and treatment related problems with 
HIV-infected patients in their series. Based on their limited numbers, a recommendation 
was made to include HIV infection as a prognostic factor in the WHO scoring system. 
Although our numbers are small, the occurrence of mortalities amongst patients with 
CD4 counts less than 200 cells /uL provides evidence of poor outcomes. The findings of 
our study do not confirm that HIV infection itself is a poor prognostic factor, unless the 
CD4 count is less than 200 cells l\\L, especially in the background of co-morbid illnesses. 
Such patients with CD4 counts < 200 cells/ul are noted to present with more advanced 
stage disease, compromising prognosis. Since the number of patients within the 
subgroups stratified for HIV status is small, it is not possible to advocate management 
guidelines. 
The findings in this study (Figure 1) lends support to the theory postulated by Ashley 
(2002), that patients with AIDS are predisposed to choriocarcinoma possibly due to 
failure of an immune response to destroy tumour cells leading to metastatic lesions. 
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To date there is no literature providing similar findings described in this study. There is 
therefore a need for centres managing GTD to document outcomes of patients in relation 
to HIV serostatus and strong consideration should be given for the inclusion of HIV 




Clinicians should have a high index of suspicion for the diagnosis of Gestational 
Trophoblastic Disease (GTD). With the advent of ultrasound and sensitive HCG assays, 
early diagnosis of GTD is possible. The primary modality of therapy for GTD is 
chemotherapy which ensures high success rates. Patients with HIV infections and GTD 
present with varying degrees of immunosuppression. The performance status, CD4 count 
and the other parameters need to be determined on admission. 
Improvement of general conditions and chemotherapy is indicated for women with CD4 
counts more than 200 cells/uL. For patients with CD4 counts below 200 cells/uL, an 
individualized approach seems most appropriate. In these patients improvement of their 
general conditions, administration of anti-retroviral therapy, determination of FIGO stage 
and review of their condition is most appropriate. Amongst these women, cytotoxic 
chemotherapy may be indicated if the patients overall condition improves and it is judged 
safe to administer chemotherapy. Careful monitoring of all patients is necessary. Future 
studies should be directed towards multi-center trials to determine the best management 




TABLE I: WHO CLASSIFICATION GTD 
Hydatidiform mole (HM) (Benign) 
• Complete 
• Partial 
Invasive mole (IM) (Malignant) 
Choriocarcinoma (Malignant) 
Placental site trophoblastic tumour (PSTT) 
Epitheloid trophoblastic lesions 
Miscellaneous trophoblastic lesions 
• Exaggerated placental site 
• Placental site nodule or plaque 
Unclassified trophoblastic lesions 
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Disease confined to the uterus 
Disease outside of uterus, but limited to the genital structures 
Disease extends to the lungs with or without known genital 
tract involvement 
All other metastatic sites 
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TABLE III: WHO SCORING SYSTEM IN GESTATIONAL TROPHOBLASTIC 























































Brain / Liver 
>8 
Two or more 
drugs 
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4. Gastro intestinal 




































































































Pulmonary tuberculosis, pulmonary 
haemorrhage, widespread disease 
Pneumonia, pulmonary oedema, widespread 
metastases 
Pneumonia, cardiac failure, lung metastases 
Jaundice, renal failure 
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Demised - Widespread 
metastases; poor general 
condition - Pneumonia. 
Demised - Condition 
deteriorated, PTB 






Demised - Widespread 
disease; condition 
deteriorated, Pneumonia 







Demised,- initially cured 
with 12 cycles, recurred, 
received 4 cycles, 








(< 2 months) 
No 
Yes 





(> 1 year) 
KEY: 
MTX: Methotrexate 
EMACO: Etoposide, Methotrexate, Actinomycin, Cyclophosphamide, Oncovin 
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EMACO: Etoposide, Methotrexate, Actinomycin, Cyclophosphamide, Oncovin 
TCP: Thrombocytopaenia 
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• St ffl and IV 
• St I and II 
CD4 < 200 CD4>200 HIV non-
ce lis/ul cells/uJ infected 
HIV infected HIV infected 
Figure 1 
Comparison of FIGO Stages for HIV infected and HIV non-infected patients 
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